LongBio Pharma (Suzhou) Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	48.74	35.28	11.27	7.49
Research & Development	167.56	126.62	98.08	73.91
Other Operating Expenses	6.78	2.41	0.05	0.15
Operating Expenses	223.07	164.31	109.4	81.55
Operating Income	-220.55	-164.31	-109.4	-81.55
Interest Expense	-1.22	-16.86	-30.99	-16.52
Interest & Investment Income	1.35	1.35	1.33	0.77
Currency Exchange Gain (Loss)	-	-	-	0.02
Other Non Operating Income (Expenses)	0.01	0.01	0.04	0.51
EBT Excluding Unusual Items	-220.41	-179.81	-139.02	-96.78
Gain (Loss) on Sale of Investments	1.24	1.24	0.5	-
Other Unusual Items	2.98	2.98	1.2	1.04
Pretax Income	-216.18	-175.58	-137.32	-95.74
Income Tax Expense	-	-	-	0.04
Net Income	-216.18	-175.58	-137.32	-95.78
Net Income to Common	-216.18	-175.58	-137.32	-95.78
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	62	57	47	43
Shares Outstanding (Diluted)	62	57	47	43
Shares Change	-	19.32%	10.91%	-
EPS (Basic)	-3.50	-3.10	-2.89	-2.24
EPS (Diluted)	-3.50	-3.10	-2.89	-2.24
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-	-125.43	-110.27	-63.34
Free Cash Flow Per Share	-	-2.21	-2.32	-1.48
EBITDA	-216.57	-160.48	-105.86	-78.67
D&A For EBITDA	3.97	3.83	3.54	2.89
EBIT	-220.55	-164.31	-109.4	-81.55